Evidence map›Paper›PMID 36413117›Full record

ArticleHuman molecular genetics2023

Clinically relevant mouse models of Charcot-Marie-Tooth type 2S.

Paige B Martin, Sarah E Holbrook, Amy N Hicks, Timothy J Hines, Laurent P Bogdanik, Robert W Burgess, Gregory A Cox

Open access · greenAbstract read
In one paragraph

Article in Human molecular genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Exploring the relationship betweenFrontiers in neuroscience · 2023
    Pooled it
  2. Junctions in Jeopardy: the neuromuscular junction is a selective pathological target in Charcot-Marie-Tooth disease.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  3. Article
  4. The Neuromuscular Junction: A Shared Vulnerability in Aging and Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Review
  5. SARM1 Inhibition in Three Mouse Models of Charcot-Marie-Tooth Disease.Journal of the peripheral nervous system : JPNS · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Paige B MartinThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Sarah E HolbrookThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Amy N HicksThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Timothy J HinesThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Laurent P BogdanikThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Robert W BurgessThe Jackson Laboratory, Bar Harbor, ME 04609, USA.ORCID 0000-0002-9229-3407
Gregory A CoxThe Jackson Laboratory, Bar Harbor, ME 04609, USA.ORCID 0000-0003-3681-8296
Jackson Laboratory · US

Funding

Polyalanine Tails: A Novel Type of Protein Modification Implicated in NeurodegenerationR01NS102414 · NINDS · JACKSON LABORATORY · PI Robert W. Burgess, GREGORY A. COX · 2017 to 2026
$7.0M
A Resource for Mouse Models of Peripheral NeuropathyR24NS098523 · NINDS · JACKSON LABORATORY · PI BOGDANIK, LAURENT P, BURGESS, ROBERT W. · 2016 to 2019
$1.2M
NIH HHS R24 NS098523NINDS NIH HHS R01 NS102414
6 · The paper itself

Abstract

Charcot-Marie-Tooth disease is an inherited peripheral neuropathy that is clinically and genetically heterogenous. Mutations in IGHMBP2, a ubiquitously expressed DNA/RNA helicase, have been shown to cause the infantile motor neuron disease spinal muscular atrophy with respiratory distress type 1 (SMARD1), and, more recently, juvenile-onset Charcot-Marie-Tooth disease type 2S (CMT2S). Using CRISPR-cas9 mutagenesis, we developed the first mouse models of CMT2S [p.Glu365del (E365del) and p.Tyr918Cys (Y918C)]. E365del is the first CMT2S mouse model to be discovered and Y918C is the first human CMT2S allele knock-in model. Phenotypic characterization of the homozygous models found progressive peripheral motor and sensory axonal degeneration. Neuromuscular and locomotor assays indicate that both E365del and Y918C mice have motor deficits, while neurobehavioral characterization of sensory function found that E365del mutants have mechanical allodynia. Analysis of femoral motor and sensory nerves identified axonal degeneration, which does not impact nerve conduction velocities in E365del mice, but it does so in the Y918C model. Based on these results, the E365del mutant mouse, and the human allele knock-in, Y918C, represent mouse models with the hallmark phenotypes of CMT2S, which will be critical for understanding the pathogenic mechanisms of IGHMBP2. These mice will complement existing Ighmbp2 alleles modeling SMARD1 to help understand the complex phenotypic and genotypic heterogeneity that is observed in patients with IGHMBP2 variants.

Indexed as

Charcot-Marie-Tooth DiseaseDisease Models, AnimalDNA-Binding ProteinsTranscription FactorsAnimalsGene Knock-In TechniquesHumansMiceMice, Inbred C57BLMuscle WeaknessMuscular AtrophyPhenotypeDNA-Binding ProteinsIGHMBP2 protein, humanTranscription Factors

Identifiers

PMID36413117
PMCPMC10077500
OpenAlexW4309587931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.